DRAFT — content pending medical review. Do not share.

Peptide Library / Men's Health

PT-141

Also known as: Bremelanotide (approved as Vyleesi)

The libido peptide — works through the nervous system rather than blood flow, which is exactly why it's studied where the little blue pill does nothing.

Typical research dose0.5–2 mg, taken 45–60 minutes before activity
FrequencyAs needed — no more than 2–3× weekly
RouteSubcutaneous injection (nasal formats exist)
Cycle lengthAs-needed, not a daily cycle

Figures reflect protocols commonly reported in the research community — not a prescription or a recommendation.

What it is

PT-141 is a melanocortin-receptor agonist that descended from the tanning peptide Melanotan-2 — researchers noticed MT-2's, let's say, unmistakable side effect and isolated the mechanism. Unlike erectile-dysfunction drugs, which are plumbing (blood flow), PT-141 is wiring: it acts on desire pathways in the brain. An auto-injector version (bremelanotide/Vyleesi) is FDA-approved for low sexual desire in premenopausal women, giving it real human trial data.

What the research looks at

How protocols are commonly structured

0.5–2 mg subcutaneous, 45–60 minutes before intended activity. Start at the low end — the difference between 0.5 mg and 2 mg is mostly side-effect load, not effect. Community norm caps use at 2–3 times weekly; the approved product's label caps at 8 doses/month. Effects can last well beyond the evening (12–24 h reports are common). It transiently nudges blood pressure, so protocols keep it clear of uncontrolled hypertension — the same line the approved product draws.

Reconstitution & storage

Lyophilized powder; bacteriostatic-water reconstitution (calculator), refrigerate after mixing.

Research protocols, not a prescription — talk to a physician before touching anything.